Form D · Biotechnology
Amagma, Inc.
Waltham, MA · CIK 0001791617
Offering snapshot reported Dec 23, 2022 · SEC filing
- Reported sold
- $10M Offering amount: $10M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 12, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 23, 2022 | Initial | $10,000,000 | No comparison | 1 | SEC filing |
| Jun 1, 2022 | Initial | $2,275,888 | No comparison | 10 | SEC filing |
| Feb 28, 2020 | Initial | $16,369,985 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-468628
Source: Form D, filed Dec 23, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Philip Ferneau | Director |
| Jean Francois Formela | Director |
| Tillman U. Gerngross | Director, Executive |
| Vishal Patel | Director, Executive |
| Amy Schulman | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
100 Beaver St
Waltham, MA, 02453
Waltham, MA, 02453